L2M QC Spring 2025 | Recapitulating the Tumor Immune Microenvironment and Stromal Interactions with Customizable Living 3D Bioprinted Human Solid Tumor Models for High-Throughput Preclinical Oncology and Translational Drug Development

We are developing a library/biobank of in vitro 3D bioprinted living tumor models to accelerate cancer drug development and bridge the translational gap. By incorporating human cells into organ-specific proprietary 3D bioprintable hydrogels we replicate the biochemical and physical properties of the tumor microenvironment with a high degree of complexity using only bio-derived materials. By leveraging 3D bioprinting, we achieve precise spatial control of our tumor constructions to engineer truly biomimetic structures that grow into human tissues to provide high-throughput testing of new therapeutic candidates. This system can be augmented with computer vision analysis and provides the potential for machine-learning integration with biomarker and mechanism of action analysis. The main objective of this project is for the intern to conduct an in-depth market study in the pharmaceutical sector with particular emphasis on large and small biopharmaceutical developers with oncology products in the pipeline for the potential applications of our innovative humanized 3D bioprinted tumor models. Through this project the intern will interact with key industry stakeholders to assess the market potential. The insights from this exercise will be used to present a potential business model and a thorough market analysis to determine the path to follow for the commercial development of the project.

Faculty Supervisor:

Satya Prakash

Student:

Partner:

V1 Studio

Discipline:

Business

Sector:

Biotechnology; Pharmaceuticals; Health and Related Sciences & Technology

University:

McGill University

Program: